Nancy Koch

CEO at Ophirex, Inc. - Corte Madera, California, United States

Nancy Koch's Colleagues at Ophirex, Inc.
Sally Stephens

VP of Commercial Operations

Contact Sally Stephens

Sunita Rao

Senior Executive Administrator

Contact Sunita Rao

Selma Abdo

Corporate Executive Administrator and Board Liaison

Contact Selma Abdo

Dana Miletic

Operations & Contracts Administrator

Contact Dana Miletic

View All Nancy Koch's Colleagues
Nancy Koch's Contact Details
HQ
+1 415-425-7892
Location
San Francisco,California,United States
Company
Ophirex, Inc.
Nancy Koch's Company Details
Ophirex, Inc. logo, Ophirex, Inc. contact details

Ophirex, Inc.

Corte Madera, California, United States • 10 Employees
Research

Ophirex, Inc., a Public Benefit Corp. focused on treatments for acute, life-threatening illnesses, is modernizing the treatment of snakebite victims by developing an affordable, accessible, oral treatment for immediate use anywhere a snake's bite occurs.Approximately 80% of the world's population lives in close proximity to at least one venomous snake species and more than 500,000 people are killed or maimed by snakes each year worldwide.[1][2] Field treatments could help save hundreds of thousands of lives and limbs annually and provide enormous savings in healthcare costs.[2][3]Ophirex is developing a "time of bite" oral snakebite treatment that blocks the most commonly lethal component of snake venom—present in 95% of the world's venomous snakes.[4] This antidote—now in human clinical trials—can be administered immediately in the field or in the hospital to effectively stop the venom's devastating assault.[5][6][7]1. Vulnerability to snakebite envenoming: a global mapping of hotspots. www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)31224-8/fulltext2. Strategy for a globally coordinated response to a priority neglected tropical disease: Snakebite envenoming. https://doi.org/10.1371/journal.pntd.00070593. Snakebite: An Exploratory Cost-Effectiveness Analysis of Adjunct Treatment Strategies. www.ajtmh.org/view/journals/tpmd/99/2/article-p404.xml4. A Review and Database of Snake Venom Proteomes. https://pubmed.ncbi.nlm.nih.gov/28927001/5. Varespladib (LY315920) Appears to Be a Potent, Broad-Spectrum, Inhibitor of Snake Venom Phospholipase A2 and a Possible Pre-Referral Treatment for Envenomation. https://pubmed.ncbi.nlm.nih.gov/27571102/6. Varespladib (LY315920) and Methyl Varespladib (LY333013) Abrogate or Delay Lethality Induced by Presynaptically Acting Neurotoxic Snake Venoms. www.ncbi.nlm.nih.gov/pmc/articles/PMC7076770/7. Broad-spectrum Rapid Antidote: Varespladib Oral for Snakebite (BRAVO).https://clinicaltrials.gov/ct2/show/NCT04996264

Details about Ophirex, Inc.
Frequently Asked Questions about Nancy Koch
Nancy Koch currently works for Ophirex, Inc..
Nancy Koch's role at Ophirex, Inc. is CEO.
Nancy Koch's email address is ***@ophirex.com. To view Nancy Koch's full email address, please signup to ConnectPlex.
Nancy Koch works in the Research industry.
Nancy Koch's colleagues at Ophirex, Inc. are Matthew Lewin, Sally Stephens, Sunita Rao, Brandi Ritter, Selma Abdo, Dana Miletic, Kathleen Dotson and others.
Nancy Koch's phone number is +1 415-425-7892
See more information about Nancy Koch